Diabetic Gastroparesis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image

New

Diabetic Gastroparesis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Report
185 Pages
April 2025
Region: Global
TechSci Research
ID: 5900044

The Diabetic Gastroparesis Treatment Market was valued at USD 2.89 Billion in 2024, and is expected to reach USD 3.47 Billion by 2030, rising at a CAGR of 3.23%. This market addresses the management of diabetic gastroparesis, a complication of diabetes marked by delayed stomach emptying. As diabetes cases surge globally, so too does the prevalence of gastroparesis, intensifying the demand for effective treatment options.

According to a 2025 study in Frontiers, gastrointestinal symptoms affect 5% to 12% of diabetic individuals, highlighting the need for improved diagnostic and treatment solutions. The market spans pharmaceuticals, dietary modifications, and medical devices, with key products including prokinetic agents, antiemetics, and nutritional support tools. These treatment modalities aim to alleviate symptoms like nausea, vomiting, abdominal pain, and indigestion, ultimately enhancing patients’ quality of life. The growing emphasis on patient-centric care and innovative therapies continues to reshape this evolving healthcare landscape.

Key Market Drivers

Rising Prevalence of Diabetes

A significant driver of the Global Diabetic Gastroparesis Treatment Market is the escalating prevalence of diabetes worldwide. Both type 1 and type 2 diabetes have reached alarming levels, with WHO data showing an increase in global diabetes cases from 200 million in 1990 to 830 million in 2022. Among these individuals, approximately 20% experience diabetic gastroparesis due to nerve damage affecting stomach motility. The link between chronic hyperglycemia and gastrointestinal complications means that as diabetes becomes more widespread, so does the incidence of gastroparesis. Notably, in 2022, 14% of adults aged 18+ had diabetes, and over half of diabetic adults aged 30+ remained untreated - particularly in low- and middle-income countries. This growing diabetic population continues to fuel demand for effective treatment options that address gastroparesis symptoms and prevent further complications, positioning this segment as a critical focus within global healthcare.

Key Market Challenges

Limited Treatment Options

Despite progress in managing diabetic gastroparesis, the market still struggles with limited treatment options. The primary drugs used - prokinetic agents and antiemetics - offer only partial relief and are not effective for all patients. This narrow pharmaceutical toolkit leaves many individuals without adequate solutions for persistent symptoms like nausea, bloating, and abdominal pain.

The lack of diverse and universally effective medications restricts clinicians' ability to personalize treatment and achieve consistent patient outcomes. Moreover, when standard therapies fail, patients often endure ongoing discomfort, leading to diminished quality of life. Healthcare providers also face difficulty managing a condition that lacks sufficient therapeutic diversity. Addressing this challenge requires greater investment in R&D to develop novel drugs, improve existing formulations, and introduce more targeted treatment approaches capable of catering to a wider range of patient responses.

Key Market Trends

Personalized Medicine

Personalized medicine is gaining momentum in the Global Diabetic Gastroparesis Treatment Market as a transformative trend focused on tailoring treatments to individual patient needs. Since diabetic gastroparesis presents differently across patients, personalization enables more precise and effective symptom management. By factoring in each patient’s medical history, symptom severity, and therapeutic response, healthcare providers can optimize treatment strategies - choosing between drug classes like prokinetic agents, antiemetics, or alternative therapies as appropriate. This customized approach improves efficacy, reduces side effects, and enhances patient satisfaction. The rise of personalized medicine underscores a shift toward targeted care, where data-driven decisions and individualized protocols support better health outcomes and address the variability inherent in diabetic gastroparesis cases.

Key Market Players

ANI Pharmaceuticals, Inc.
Evoke Pharma
Janssen Pharmaceutica N.V
Teva Pharmaceuticals Inc.
Pfizer Inc.
Salix Pharmaceuticals, Inc.
Allergan
Novartis AG
SCHWITZ BIOTECH
Wellona Pharma

Report Scope:

In this report, the Global Diabetic Gastroparesis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Diabetic Gastroparesis Treatment Market, By Type:

Grade 2 (Compensated Gastroparesis)
Grade 3 (Gastric Failure)

Diabetic Gastroparesis Treatment Market, By Route of Administration:

Oral
Parenteral
Nasal

Diabetic Gastroparesis Treatment Market, By Drug Class:

Gastroprokinetic Agents
Antiemetic Agents
Antihistamines
Others

Diabetic Gastroparesis Treatment Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Diabetic Gastroparesis Treatment Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Gastroparesis Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Gastroparesis Treatment Market Outlook

4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Grade 2(Compensated Gastroparesis), Grade 3(Gastric Failure))
4.2.2. By Drug Class (Gastroprokinetic Agents, Antiemetic Agents, Antihistamines, Others)
4.2.3. By Route of Administration (Oral, Parenteral, Nasal)
4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.5. By Region
4.2.6. By Company (2024)
4.3. Market Map
4.3.1. By Type
4.3.2. By Drug Class
4.3.3. By Route of Administration
4.3.4. By Distribution Channel
4.3.5. By Region

5. Asia Pacific Diabetic Gastroparesis Treatment Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Drug Class
5.2.3. By Route of Administration
5.2.4. By Distribution Channel
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Diabetic Gastroparesis Treatment Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Drug Class
5.3.1.2.3. By Route of Administration
5.3.1.2.4. By Distribution Channel
5.3.2. India Diabetic Gastroparesis Treatment Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Drug Class
5.3.2.2.3. By Route of Administration
5.3.2.2.4. By Distribution Channel
5.3.3. Australia Diabetic Gastroparesis Treatment Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Drug Class
5.3.3.2.3. By Route of Administration
5.3.3.2.4. By Distribution Channel
5.3.4. Japan Diabetic Gastroparesis Treatment Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Drug Class
5.3.4.2.3. By Route of Administration
5.3.4.2.4. By Distribution Channel
5.3.5. South Korea Diabetic Gastroparesis Treatment Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Drug Class
5.3.5.2.3. By Route of Administration
5.3.5.2.4. By Distribution Channel

6. Europe Diabetic Gastroparesis Treatment Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Class
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Diabetic Gastroparesis Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Class
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Germany Diabetic Gastroparesis Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Class
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Spain Diabetic Gastroparesis Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Class
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
6.3.4. Italy Diabetic Gastroparesis Treatment Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Drug Class
6.3.4.2.3. By Route of Administration
6.3.4.2.4. By Distribution Channel
6.3.5. United Kingdom Diabetic Gastroparesis Treatment Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Drug Class
6.3.5.2.3. By Route of Administration
6.3.5.2.4. By Distribution Channel

7. North America Diabetic Gastroparesis Treatment Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Type
7.2.3. By Distribution Channel
7.2.4. By Route of Administration
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Diabetic Gastroparesis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Class
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Diabetic Gastroparesis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Class
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Diabetic Gastroparesis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Class
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel

8. South America Diabetic Gastroparesis Treatment Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Type
8.2.3. By Distribution Channel
8.2.4. By Route of Administration
8.2.5. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Diabetic Gastroparesis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Class
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Argentina Diabetic Gastroparesis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Class
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Colombia Diabetic Gastroparesis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Class
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Diabetic Gastroparesis Treatment Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Diabetic Gastroparesis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug Class
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. Saudi Arabia Diabetic Gastroparesis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. UAE Diabetic Gastroparesis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug Class
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. Egypt Diabetic Gastroparesis Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Drug Class
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel

10. Market Dynamics

10.1. Drivers
10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. Global Diabetic Gastroparesis Treatment: SWOT Analysis

13. Porter’s Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. ANI Pharmaceuticals, Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (In case of listed)
14.1.5. Recent Developments
14.1.6. SWOT Analysis
14.2. Evoke Pharma
14.3. Janssen Pharmaceutica N.V
14.4. Teva Pharmaceuticals Inc.
14.5. Pfizer Inc.
14.6. Salix Pharmaceuticals, Inc.
14.7. Allergan
14.8. Novartis AG
14.9. SCHWITZ BIOTECH
14.10. Wellona Pharma

15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned

ANI Pharmaceuticals, Inc.
Evoke Pharma
Janssen Pharmaceutica N.V
Teva Pharmaceuticals Inc.
Pfizer Inc.
Salix Pharmaceuticals, Inc.
Allergan
Novartis AG
SCHWITZ BIOTECH
Wellona Pharma

Table Information

Report Attribute	Details
No. of Pages	185
Published	April 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 2.89 Billion
Forecasted Market Value ( USD ) by 2030	$ 3.47 Billion
Compound Annual Growth Rate	3.2%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4096EUR$4,500USD£3,479GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5006EUR$5,500USD£4,252GBP